je.st
news
Tag: announce collaboration
Immunocore And Lilly Announce Immunotherapy-Based Clinical Trial Collaboration In Melanoma
2015-07-01 08:13:50| drugdiscoveryonline Home Page
Immunocore Limited and Eli Lilly and Company recently announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore’s lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma
Tags: trial
clinical
collaboration
announce
Celgene and Juno Announce Ten-Year Collaboration to Advance...
2015-06-29 23:23:19| Biotech - Topix.net
Broad strategic collaboration leveraging combined immunology expertise and assets to develop and commercialize novel immunotherapies for the treatment of cancer and autoimmune diseases Celgene to make initial payment of approximately $1 billion which includes the purchase of ~9.1 million shares of Juno stock at $93.00 per share, with potential to increase its stake over time SUMMIT, N.J. & SEATTLE-- -- Celgene Corporation and Juno Therapeutics, Inc. announced today a global collaboration for the development and commercialization of immunotherapies.
Tags: advance
collaboration
announce
juno
Soitec And Shanghai Industrial Technology Research Institute (SITRI) Announce Collaboration On High-Performance RF-SOI Technology
2015-06-09 08:09:48| rfglobalnet Home Page
Soitec, a world leader in generating and manufacturing revolutionary semiconductor materials for the electronics and energy industries, and Shanghai Industrial µTechnology Research Institute (SITRI), a leader in “More than Moore” technology R&D and commercialization, announced recently the signature of a collaboration agreement.
Tags: research
technology
industrial
institute
Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
2015-06-01 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & BERKELEY, Calif. Studies to Evaluate the Combination of Dynavaxs SD-101 with Two Immunotherapies from Mercks Pipeline, KEYTRUDA (pembrolizumab) and MK-1966 Collaboration Includes First-in-human Study for MK-1966, a New Investigational Anti-interleukin-10 (anti-IL-10) Immunomodulator from Mercks Rapidly Growing Immuno-oncology Pipeline KENILWORTH, N.J. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orMerck Investor Relations:Justin Holko, 908-740-1879orDynavax Investor/Media Relations:Michael Ostrach, 510-665-7257 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: combination
collaboration
announce
investigating
Amgen and Merck Announce Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combination with KEYTRUDA (pembrolizumab) in Patients with Head and Neck Cancer
2015-05-29 14:30:32| Merck.com - Product News
Dateline City: THOUSAND OAKS, Calif. and KENILWORTH, N.J. Companies Also Plan to Initiate Phase 3 Trial in Combination for Advanced Melanoma THOUSAND OAKS, Calif. and KENILWORTH, N.J., - May 29, 2015 Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgens investigational oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Language: English read more
Tags: with
support
head
studies
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »